Vaccine nationalism and the dynamics and control of SARS-CoV-2

Caroline E. Wagner,^{1,*,†} Chadi M. Saad-Roy,^{2,*,†} Sinead E. Morris,³ Rachel E. Baker,^{4,5} Michael J. Mina,⁶ Jeremy Farrar,⁷ Edward C. Holmes,⁸ Oliver G. Pybus,⁹ Andrea L. Graham,⁴ Ezekiel J. Emanuel,¹⁰ Simon A. Levin,⁴ C. Jessica E. Metcalf,^{4,11} Bryan T. Grenfell^{4,11,†}

¹ Department of Bioengineering, McGill University, Montreal QC H3A 0C3, Canada ² Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton NJ 08540, USA ³ Department of Pathology and Cell Biology, Columbia University Medical Center, New York NY 10032, USA ⁴ Department of Ecology and Evolutionary Biology, Princeton University, Princeton NJ 08540, USA ⁵ Princeton High Meadows Environmental Institute, Princeton University, Princeton NJ 08540, USA ⁶ Departments of Epidemiology and Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston MA 02115, USA ⁷ The Wellcome Trust, London, UK ⁸ Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia ⁹ Department of Zoology, University of Oxford, Oxford, UK ¹⁰ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA ¹¹ Princeton School of Public and International Affairs, Princeton University, Princeton NJ 08540, USA *These authors contributed equally to this work; [†]To whom correspondence should be addressed: caroline.wagner@mcgill.ca (CEW); csaadroy@princeton.edu (CMSR); grenfell@princeton.edu (BTG)

Vaccines provide powerful tools to mitigate the enormous public health and 1 economic costs that the ongoing SARS-CoV-2 pandemic continues to exert 2 globally, yet vaccine distribution remains unequal between countries. To ex-3 amine the potential epidemiological and evolutionary impacts of 'vaccine nationalism', we extend previous models to include simple scenarios of stock-5 piling. In general, we find that stockpiling vaccines by countries with high 6 availability leads to large increases in infections in countries with low vaccine availability, the magnitude of which depends on the strength and duration 8 of natural and vaccinal immunity. Additionally, a number of subtleties arise 9 when the populations and transmission rates in each country differ depending 10 on evolutionary assumptions and vaccine availability. Furthermore, the move-11 ment of infected individuals between countries combined with the possibility of 12 increases in viral transmissibility may greatly magnify local and combined in-13 fection numbers, suggesting that countries with high vaccine availability must 14 invest in surveillance strategies to prevent case importation. Dose-sharing is 15 likely a high-return strategy because equitable allocation brings non-linear 16 benefits and also alleviates costs of surveillance (e.g. border testing, genomic 17 surveillance) in settings where doses are sufficient to maintain cases at low 18 numbers. Across a range of immunological scenarios, we find that vaccine 19 sharing is also a powerful tool to decrease the potential for antigenic evolution, 20 especially if infections after the waning of natural immunity contribute most to 21 evolutionary potential. Overall, our results stress the importance of equitable 22 global vaccine distribution. 23

The SARS-CoV-2 pandemic has led to more than 100 million infections and nearly 3 million fatalities to date (*1*). Effective vaccines (e.g. (2–4)) have now been approved and are actively being deployed, but numerous important questions remain. Eventually, community immunity

2

may be attained through the deployment of vaccines; however if and when this occurs will be
contingent on the characteristics of natural and vaccinal immunity (5–7) in conjunction with
SARS-CoV-2 evolutionary potential.

30

Due to strong public and political pressures and fear of waning immunity, some countries 31 with high vaccine availability are currently resorting to 'vaccine nationalism': stockpiling vac-32 cines to prioritize rapid access to their citizenry (8). Recently, the World Health Organization 33 recognized that delayed access to vaccines in countries with low vaccine availability may lead 34 to more evolutionary potential for immune escape (9). Indeed, at the time of writing, 86 and 35 91 doses per 100 individuals have been administered in the United States and United Kingdom, 36 respectively, while an average of 14 and 2.1 doses per 100 individuals have been administered 37 in India and across Africa, respectively (10). The emergence of future variants capable of evad-38 ing natural or vaccinal immune responses could threaten containment efforts globally. These 39 concepts underlie the development of a number of policy tools, including the existing COVAX 40 initiative. Furthermore, to ensure that vaccine distribution is ethically-sound and equitable, the 41 "Fair Priority Model" has been proposed (11–13) as a potential replacement to the currently 42 planned proportional allocation (by population size) from COVAX. 43

44

Prior work exploring optimal prophylactic vaccine allocation for minimizing the final epi-45 demic size of a fully immunizing infection (i.e. one that can be modeled using a susceptible-46 infected-recovered (SIR) framework) found that when interaction between communities (or 47 countries) is considered, equal vaccine distribution is increasingly advantageous in terms of 48 minimizing case numbers (14). Modeling studies have also shown that coordinated influenza 49 vaccine sharing would reduce the financial and infection burden of influenza outbreaks glob-50 ally (15). Similar problems related to optimizing vaccine allocation have also been explored in 51 networks with community structure (16) as well as in the face of economic constraints (17) and 52

coalition formation (18), and for SARS-CoV-2 with age- (and contact-) structure (19, 20). We 53 have recently shown that the strength and duration of immunity elicited following infection or 54 one or two doses of a vaccine will have a crucial impact on the medium-term epidemiological 55 and potential evolutionary outcomes (5, 6). Here we extend these analyses to address potential 56 epidemiological and evolutionary consequences of policies of vaccine nationalism or equitable 57 access for a range of assumptions regarding the robustness of host immune responses. In real-58 ity, vaccine distribution is a public goods problem, and the optimal "global" allocation projected 59 based on evolutionary and immunological uncertainties may differ from national optima due to 60 the actual economic landscape of each country. In all cases, however, the reduction in the po-61 tential for novel strains to arise associated with minimizing the global infection burden is likely 62 critical. 63

64




Figure 1: Schematic depicting the two-country model. The underlying immuno-epidemiological models for each country are based on (5, 6). Vaccines are allocated by the high access region (HAR) to the low access region (LAR). In the coupled framework, immigration of infected individuals between the countries is considered, and the national transmission rate depends on potential transmission increases (PTIs) in both countries, shown schematically as solid and striped virus particles in the HAR and LAR, respectively. In the decoupled framework, no immigration occurs, and the transmission rate is not influenced by PTIs. Full model details are provided in the Supplementary Materials.

We consider a trans-national extension of our model comprised of two countries with possi-65 bly different population sizes and seasonal transmission patterns. One country, the high access 66 region (HAR), chooses to allocate a fraction f of the total vaccine supply to the low access 67 region (LAR). The underlying immuno-epidemiological models for both countries account for 68 both the duration of natural and vaccinal immunity and the residual decrease in host suscepti-69 bility to infection (relative to immunologically naive individuals) after full natural or vaccinal 70 immunity has waned; these models are described in detail in (5, 6), where the more detailed 71 structure (6) accounts for immunity after one or two vaccine doses. In the first "decoupled" 72 framework (top panel of Figure 1), we assume that the epidemiological dynamics of both coun-73

tries are entirely independent with the exception of their respective vaccination rates, and we 74 also compute a measure for the global potential for viral evolution of immune escape (6). In the 75 second "coupled" framework (bottom panel of Figure 1), we allow for immigration of infected 76 individuals between the countries at rate η (17). Additionally, we approximate the stochastic 77 occurrence of potential transmission increases (PTIs) in each country: briefly, if the 'potential 78 net viral adaptation rate' (see Supplementary Materials, Figure 5, and (6)) exceeds a thresh-79 old, then there is a non-zero probability that the transmission rate in both countries increases. 80 This follows evidence of enhanced binding of the SARS-CoV-2 spike protein receptor binding 81 domain (RBD) with the ACE2 receptor in more contagious SARS-CoV-2 variants, as well as 82 potentially higher viral loads (21). Structural changes to the spike protein furin cleavage site 83 (e.g. at site 681) may also contribute to increased viral transmissibility (22). In this way, this 84 assumption represents a pessimistic scenario where the evolution of pathogen immune escape 85 is inevitably accompanied by increases in transmission, although we also compare our results 86 with the more optimistic scenario where transmission increases do not occur (note that we are 87 not modeling the complexities of variant dynamics and evolution explicitly). In reality, trans-88 mission increases may plateau, and viral evolution may have more subtle effects on disease 89 transmission including modulating the susceptibility of partially immune hosts. The full math-90 ematical details for both frameworks are described in the Supplementary Materials. 91

92

We begin with the decoupled framework and the simpler underlying 'one-dose' vaccination model from (5) to compute the long-term equilibrium fraction of infections in both countries under a range of epidemiological and immunological scenarios. Then, with specific dosing regimes (6), we examine the short- and medium-term epidemiological dynamics and the global potential for evolution with the sharing of vaccines. Next, using the coupled framework, we compute national and combined case numbers in the medium term given different degrees of vaccine allocation from the HAR to the LAR for different immigration rates and average relative

reproduction numbers. We do so for total as well as severe cases, with the expectation that the
 number of severe cases may be indicative of infections requiring hospitalization or the clinical
 burden of Covid-19, while the number of total cases reflects all infections regardless of severity.
 Finally, we compare the results of the coupled and decoupled frameworks for specific scenarios.

Results and Discussion

Decoupled Framework

The dynamics of prophylactic vaccine distribution strategies are well understood when infec-106 tions lead to recovery and lifelong immune protection (SIR) (14). However, natural and vaccinal 107 immunity to SARS-CoV-2 is likely not lifelong, yet complete re-susceptibility after the waning 108 of immunity, as is assumed in susceptible-infected-recovered-susceptible (SIRS) frameworks, 109 is also unlikely. Thus, we generalize across the strength and duration of immune responses with 110 appropriate mathematical models (5, 6). We first ignore the complexities of dosing regimes and 111 extend the model in (5) to consider vaccine sharing in the decoupled framework (top panel of 112 Figure 1) under the assumption that a single immune category exists for vaccinated individu-113 als, and that vaccinal immunity may wane at a rate distinct from natural immunity. Since we 114 assume that the infection dynamics in both countries are only coupled through their respective 115 vaccination rates, a unique equilibrium of total infections exists (either disease-free or endemic; 116 see supplement and (5) for details). To examine the long-term epidemiological effects of vac-117 cine nationalism, we compute the total fraction of infections at equilibrium as the proportion of 118 vaccines shared between countries is varied. In other words, for a fixed global vaccination rate 119 u_{tot} (determined by the maximal rate of administration of the first dose $u_{0,tot}$ and the inter-dose 120 period, see Methods) and for a fraction f of vaccines allocated from the HAR to the LAR, the 121 vaccination rates in the HAR and LAR are $(1-f)\nu_{\rm tot}$ and $f\nu_{\rm tot}$, respectively. We examine four 122 immunity scenarios that range from very poor to robust natural and vaccinal immune responses 123 (Figure 2). 124

125

When the characteristics of both countries are the same, sharing vaccines always decreases 126 or maintains the total fraction of infections at the long-term equilibrium (see Keeling (14) for 127 the SIR extreme with a focus on two differently-sized populations). The intuition for this result 128 is apparent from examining the underlying values for each country (Figure 2C). The total frac-129 tion of infections are minimized whenever one of the countries does not vaccinate beyond the 130 rate needed for herd immunity. Additionally, sharing does not have an appreciable impact on 131 the total fraction of infections at equilibrium when vaccination rates are too low (Figure 2A, top 132 panel), or overall transmission rates are more elevated and host immune responses are poorer 133 (Figure 2B, top panel). Because of nonpharmaceutical interventions (NPIs) or intrinsic factors 134 (e.g. population density (23) or vulnerabilities (24)), transmission rates in the two countries may 135 be asymmetric. If there is less disease transmission in the HAR (modelled as a reduction in the 136 transmission rate), then the 'optimal' fraction of vaccines shared to minimize the combined 137 equilibrium fraction of infections crucially depends on the magnitude of the vaccination rate. 138 If vaccine supplies are low and immune responses very poor, then sharing only a very small 139 fraction of the vaccine supply is epidemiologically beneficial in terms of decreasing the overall 140 burden. For stronger immune responses, augmenting vaccine sharing rates becomes increas-141 ingly beneficial from an epidemiological perspective, as the protective effects of the vaccine are 142 maintained for longer within the population (compare the columns of the middle row of Figure 143 2A). Similarly, as vaccine supplies increase (compare the coloured curves in the middle row of 144 Figure 2A), the minimum value of infections occurs for increasingly large values of f, or frac-145 tions of vaccines shared. Eventually, when global vaccination rates are high, even for very poor 146 host immune responses, this minimum is attained when more than half of the vaccine supply is 147 allocated to the LAR (leftmost panel of middle row of Figure 2A). By symmetry, the opposite 148 occurs if there is less transmission in the LAR. These trends are further magnified if overall 149 transmission rates are increased (Figure 2B). To further emphasize these effects, we present 150




Figure 2: Long-term equilibrium of the average fraction of infections. In all panels, immunity scenarios are as follows: *very* poor immunity, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 0.8$ years, $\epsilon = 0.8$; poor immunity, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 1$ year, $\epsilon = 0.7$; intermediate immunity, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 1.5$ years, $\epsilon = 0.6$; robust immunity, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 2$ years, $\epsilon = 0.5$. In the scenario with asymmetrical transmission rates between the two countries, the transmission rate in the country with lower transmission is taken to be 80% of the value in the symmetric case. In the scenarios with overall higher transmission rates (panel *B*), this same asymmetric assumption is made in addition to the baseline symmetric transmission rate being elevated by 30% relative to the value in panels (*A*). (*C*)–(*E*) Illustrations of the equilibrium fraction of infections in each country with the very poor immunity scenario, for: (*C*) symmetric transmission (lower in HAR) with $\nu_{\text{tot}} = 0.004$; (*D*) asymmetric transmission (lower in HAR) with $\nu_{\text{tot}} = 0.004$; (*E*) asymmetric transmission rate is $\beta = \frac{2.3}{5}$.

the long-term equilibrium of each country under representative scenarios in Figures 2C–2E. In particular, the comparison between Figures 2D and 2E illustrates the importance, and indirect benefit, of increasing vaccine supply. The relative sizes of the HAR and LAR populations can have important consequences for the fraction of vaccine allocation that minimizes the weighted fraction of infections (Fig. S1, S2). Overall, these results highlight the importance of continued NPIs that decrease transmission, such as rapid-testing and physical distancing, in conjunction with ramping up vaccination and sharing vaccine supplies equitably to decrease overall burden.

To consider the near- and medium-term dynamic epidemiological effects of vaccine shar-159 ing, in Figure 3 we explore the landscapes of immunity and infections across multiple scenarios 160 for otherwise-symmetric countries (i.e. population size and seasonal transmission rates). In all 161 scenarios, vaccine supply is assumed to be limited initially in the HAR (modeled as a one dose 162 policy, a lower maximal rate of administration of the first dose $\nu_{0,tot}$, and no sharing (f = 0)) 163 and then is assumed to increase. In conjunction with an increase in $\nu_{0,tot}$, we allow for a tran-164 sition to the recommended two-dose strategy ($\frac{1}{\omega} = 4$ weeks, right two columns of Figure 3), 165 and/or the initiation of equal sharing (f = 0.5) with the LAR (which is assumed to distribute 166 vaccines using the same strategy as the HAR) may be initiated (second and fourth columns of 167 Figure 3). 168

169

Intuitively, if one-dose immunity is robust (bottom panel of Figure 3), then transitioning to a two-dose strategy leads to fewer individuals with robust vaccinal immunity, in turn giving rise to substantial increases in infections in both in the short- and medium-term (compare the corresponding scenarios of the bottom panel of Figure 3 and see also (*6*)). In such a situation, 'one-dose' strategies (*i.e.* either the first dose of a 2-dose vaccine or the unique dose of a 1-dose vaccine) with equal sharing between countries suppress overall burden. On the other hand, if one-dose immunity is poor, switching to the recommended two-dose regimen prevents the ac-

No sharing (f=0)

3 4 5 1 2

Time (years)

3 4

LAR

LAR

HAR

0.06

0.04

0.02

0.00 1.00

0.75

0.50

0.2

0.00

0.06

2

HAR

One-dose policy

Switch to two-dose strategy

Severe

Cas

Fraction of population

0.06

0.04

0.02

0.00

1.00

0.75

0.50

0.25

0.00

0.06

Equal sharing (f=0.5)

3 4 5 1

HAR

Time (years)

2 3


LAR


4 5

LAR

Severe

HAR





Robust vaccinal immunity after one dose




Figure 3: Immune landscapes and infections in both countries under a range of vaccination strategies and assumptions related to robustness of immune responses. Note that the color scheme is as in Figure 1. In all panels, vaccination begins after week 48. *Poor vaccinal immunity after one dose* is represented by $\frac{1}{\delta_1} = 0.25$ year and $\epsilon_1 = 0.9$, whereas *robust vaccinal immunity after one dose* is represented by $\frac{1}{\delta_1} = 0.25$ year and $\epsilon_1 = 0.9$, whereas *robust vaccinal immunity after one dose* means $\frac{1}{\delta_1} = 1$ year and $\epsilon_1 = 0.7$. All other parameters values including the procedure for the calculation of severe cases are described in Supplementary Materials. In both the top and bottom panels: the top row depicts a switch from a maximum first-dose administration rate of 1% to 3% after week 60, whereas it is 1% to 5% for the bottom row (and concurrent with sharing, if it occurs).

One-dose policy

Switch to two-dose strategy

cumulation of individuals with waned one-dose immunity and thus potentially larger infections 177 peaks in the longer term (top panel, Figure 3). If poor one-dose immunity nevertheless reduces 178 severity of infection after waning (unlike our pessimistic assumption), then the predicted clin-179 ical burden of severe cases would likely be lower. Finally, if one-dose immunity is poor and 180 a one-dose policy is pursued, the first infection peak after ramping up vaccination in the HAR 181 may be higher without sharing (top left panel of Figure 3). This counter-intuitive finding arises 182 due to the large accumulation of individuals with waned one-dose immunity who experience 183 infection. This highlights the important role for population-level susceptibility (modulated by 184 natural and vaccinal immune responses) and its dynamical interplay with transmission in deter-185 mining the timing and burden of infections. The effects of different NPI scenarios, transmission 186 patterns, and vaccination rates in either the HAR or LAR can be further explored with the online 187 application (https://grenfelllab.shinyapps.io/vaccine-nationalism/). 188

189

The accumulation of individuals with various immunity phenotypes (i.e. waned one-dose 190 immunity or immunity following natural infection) may also lead to different evolutionary 191 outcomes depending on the vaccine sharing scheme pursued. Current evidence suggests that 192 adaptive immune responses following natural infection with SARS-CoV-2 are fairly robust and 193 long-lasting (25, 26), although this may be less certain in the context of subsequent infection 194 with variant strains (27, 28). Encouragingly, studies indicate that previously-infected hosts are 195 largely protected (clinically and against breakthrough infections) against emerging variants af-196 ter a single vaccine dose (29). Thus far, the duration and strength of this protection towards 197 existing strains and potential emerging variants remain unknown. In Figure S3, we use the evo-198 lutionary framework from (6) to project the potential net viral adaptation rate (see Methods and 199 online application for additional scenarios). Overall, we find that uncertainties in evolutionary 200 outcomes dominate our projections, echoing previous findings (6) (Figure S3, and online appli-201 cation). However, if the evolutionary potential for immune escape is highest among infections 202

in hosts with natural immunity, then sharing vaccines always decreases global evolutionary potential (Figure S3) in the decoupled framework. Overall, when immunity after a single vaccine
dose is robust, natural and vaccine-derived immunity will limit evolutionary advances relative
to the scenario with poor single dose immunity (compare the top and bottom panels of Figure
S3). However, if immunity is partial or waning, ongoing transmission might accelerate adaption, supporting the need for continued monitoring of variants and their interaction with natural
and vaccine-derived immunity.

210

Another intuitive result is that, in the LAR, sharing vaccines leads to increases in population immunity (for any dosing regime) and thus a decrease in infections and burden in the short term, even with poor one-dose immunity. In general, in the HAR, sharing decreases population immunity and increases infections in the short term. However, these changes are minimal and likely acceptable given the combined decrease in infections, illustrating the long term benefits of vaccine sharing.

217 Coupled Framework

So far, we have assumed that the countries have decoupled disease dynamics. This simplification for tractability ignores infection importation as well as the possible emergence of variants from regions with more persistent infections. The issues that arise from the global circulation of SARS-CoV-2, particularly the variants of concern, are of considerable public health importance. Thus, we next explore these effects using the coupled framework presented in the bottom panel of Figure 1.

224

In Figure 4, we plot the cumulative number of total and severe cases (see Supplementary Materials for details) assuming equal population sizes in both countries from the time of vaccine introduction until 5 years after the pandemic onset in the HAR, LAR, and combined, as well

as the projected number of PTIs to have occurred in both regions by the end of the 5 year 228 period. We do so for various vaccine allocation fractions between the HAR and LAR, as well 229 as a range of immigration rates assuming symmetric transmission rates (Figures 4A and 4C) 230 and relative mean reproduction numbers assuming constant immigration rates (Figures 4B and 231 4D, see Methods). In Figures 4A and 4B we assume that infection following waned natural 232 immunity contributes the most to viral adaptation, while in Figures 4C and 4D we assume that 233 infection following waned vaccinal immunity, and one-dose immunity in particular, contributes 234 the most. 235




Figure 4: Heat maps depicting total and severe cases from the time of vaccine onset ($t_{vax} = 48$ weeks) through the end of the 5 year period for both countries (leftmost two columns), the HAR (third and fourth columns from the left), the LAR (fifth and sixth columns from the left), as well as the combined number of PTIs to have occurred in both countries at the end of 5 years (rightmost column). Each grid-point denotes the mean value of 100 simulations. The population of both countries is taken to be the same. Each area plot is internally normalized, such that the largest value in each plot is 1. The *x*-axis indicates the fraction of vaccines retained by the HAR (i.e. 1 - f); thus the far right of a plot is the scenario where the HAR retains all vaccines (f = 0). In A and C, both countries have the same average transmission rate (\bar{R}_0 , see Methods), and the immigration rate η is varied. In B and D, the immigration rate is fixed at $\eta = 0.01$, and the relative mean transmission rate in the LAR, i.e. $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$, is varied between 0.5 and 2. The seasonality of the transmission rates in both countries and periods of NPI adoption are identical and as described in the Methods. In all simulations, we assume a two-dose strategy throughout, i.e. $\frac{1}{\omega} = 4$ weeks, and take the maximal rate of administration of the first dose to be $\nu_{0,\text{tot}} = 2\%$. Assumed immunological parameters are $\frac{1}{\delta_1} = 1$ year, $\epsilon = 0.7$, $\epsilon_{V_1} = 0.1$, $\epsilon_{V_2} = 0.05$, $\epsilon_2 = 0.7$, $\frac{1}{\rho_2} = 1$ year, and the one- to two-dose immune response ratio is $x_e = 0.8$ (see Methods). In the top panel (A and B), we assume that infection after waned natural immunity contributes more to potential viral adaptation, and take $w_{IS} = 0.8$, $w_{IS1} = 0.2/x_e$, and $w_{IS2} = 0.2$ (see Methods). In the bottom panel (C and D), we assume that infection after waned vaccinal immunity contributes more to potential viral adaptation, and take $w_{IS} = 0.4$, $w_{IS1} = 0.8$, and $w_{IS2} = 0.8 \times x_e$ (see Meth

For equal population sizes and symmetric transmission rates, a weak dependence of total 236 and severe cases as well as PTIs on the immigration rate η is observed, regardless of whether 237 infection after waned natural or vaccinal immunity is assumed to contribute more to viral evo-238 lution (Figures 4A and 4C). Additionally, equal vaccine sharing (i.e. f = 0.5) minimizes total 239 PTIs and combined total cases in both scenarios. When natural infections contribute more to 240 evolution (Figure 4A) and η is low, the HAR must retain an increasing share of the vaccines to 241 minimize local total cases as the immigration rate increases, but this is done at the expense of 242 more cases in the LAR and PTIs. Notably, for $f \approx 0$, severe cases are minimized regardless 243 of the immigration rate in the HAR and maximized in the LAR, which may have important 244 clinical consequences. When infection following waned vaccinal immunity contributes more to 245 viral evolution, this approach is no longer advantageous for the HAR, and the retained vaccine 246 fraction sets the observed case numbers nearly independently of the assumed immigration rate. 247 Further, large asymmetries in vaccine sharing (i.e. f = 0 or f = 1) result in much more marked 248 relative numbers of PTIs in this scenario. 249

250

For the same total vaccine availability, the most realistic population asymmetry is that the 251 LAR has a larger population; this corresponds to low and middle income countries with more 252 fragile healthcare systems. Under this condition (Figure S4) and when infection after waned 253 natural immunity contributes more to evolution, total cases in the LAR are relatively insen-254 sitive to the amount of vaccine allocated, except for very large f; however severe cases can 255 be substantially reduced with vaccine sharing. Here, combined total cases and PTIs are mini-256 mized by minimizing cases in the HAR. When a greater number of total vaccines are available 257 (i.e. a larger $\nu_{0,tot}$, Figure S5), total and severe cases in the more populous LAR decrease 258 approximately monotonically with increasing vaccine allocation f and more equitable vaccine 259 allocation once again minimizes combined total and severe cases. When infection after waned 260 vaccinal immunity contributes more to evolution, the trends are more similar to those for sym-26

metric population sizes, and more equitable vaccine sharing is favoured for both vaccination rates $\nu_{0,\text{tot}}$ given a larger population in the LAR (Figures S4 and S5).

264

²⁶⁵ When the LAR has a smaller population (Figure S6), a relatively weak dependence of total ²⁶⁶ and severe case numbers and PTIs on η is still observed for both evolutionary scenarios, par-²⁶⁷ ticularly for higher immigration rates. However, and particularly when infection after waned ²⁶⁸ natural immunity contributes more to evolution, the minima in combined cases and PTIs are ²⁶⁹ now observed for f < 0.5, i.e. when the HAR retains more than half of the available vaccines. ²⁷⁰ Importantly, we note that additional booster doses may further change these landscapes of im-²⁷¹ munity, and consequently the projected burdens of total and severe cases.

272

The number of total and severe cases and PTIs show a greater sensitivity to the average 273 reproduction number ratio $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$ between the two countries for a fixed immigration 274 rate. Intuitively, for equal population sizes (Figure 4) and when \overline{R}_0 in the LAR country is lower, 275 having the HAR retain more than half of the vaccines (f < 0.5) is a good strategy for minimiz-276 ing total PTIs and cases, regardless of the evolutionary scenario. Indeed, the optimal vaccine 277 allocation shifts closer and closer to equal sharing as the \bar{R}_0 values of both countries approach 278 each other, along with an increase in cases. These trends are similar when the LAR has a larger 279 or smaller population than the HAR (Figures S4 and S6, respectively). 280

281

²⁸² When \bar{R}_0 in the LAR is higher, trends are more complex. In general, regardless of the rel-²⁸³ ative population size or evolutionary scenario, for a given $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$, cases in the HAR ²⁸⁴ decrease with increasing vaccine retention (smaller f), while cases in the LAR increase (Fig-²⁸⁵ ures 4, S4, S5, and S6). Severe cases in each region in particular are strongly reduced by ²⁸⁶ increased vaccine availability. The increase in cases in the LAR is increasingly large at higher ²⁸⁷ $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$. When infection after waned natural immunity contributes more to evolution

and vaccine supply is sufficiently high to reduce case numbers in the LAR, PTIs are numerous 288 when the HAR retains a large fraction of the vaccines (Figures 4B, S5B, and S6B). This is due 289 to sustained elevated case numbers in unvaccinated individuals in the LAR. On the other hand, 290 when infection following waned vaccinal immunity contributes more to evolution, then hav-29 ing the HAR (with lower transmission rates) retain a larger fraction of the vaccines minimizes 292 PTIs for any relative population size, since the high \bar{R}_0 in the LAR would result in large subse-293 quent peaks containing individuals whose vaccinal immunity has waned with sharing (Figures 294 4D, S4D, S5D, and S6D). However, this strategy also leads to highly elevated case numbers, 295 including severe cases, in the LAR. 296




Figure 5: Time series of cases and potential net viral adaptation rates. Top row: Infections in the HAR (blue) and LAR (red) for the first 5 years after pandemic onset for the coupled (left) and decoupled (middle) frameworks. Each simulation is run 100 times, with the average indicated by the solid line and the standard deviation shown with the corresponding ribbon. The average number of cumulative cases over all simulations from the time of vaccine onset $t_{vax} = 48$ weeks through the end of the 5 year period are shown in the rightmost figure for the HAR, LAR, and both countries combined for the coupled (solid) and decoupled (dashed) frameworks. Bottom row: Time series of the potential viral adaptation rate in both regions for the coupled (left) and decoupled (right) frameworks. The colors, averages and standard deviations are as described above. The dashed horizontal line denotes $e_{\text{cutoff}} = 0.01$, the assumed threshold for the occurrence of a PTI (see Methods). The average number of PTIs at the end of the 5 year period are shown in the rightmost figure for the HAR retaining all vaccines (f = 0), while the bottom panel (G-L) corresponds to equal vaccine sharing (f = 0.5). In all simulations, we take $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}} = 1.2$, $\eta = 0.01$, and assume that infection after waned natural immunity contributes primarily to evolution (i.e. $w_{IS} = 0.8$, $w_{IS1} = 0.2/x_e$, and $w_{IS2} = 0.2$). All other parameters are identical to those in Figure 4.

We note that assumptions of large \bar{R}_0 in the LAR also result in very large initial infection 297 peaks, which increase community immunity in the medium-term. These initial waves are not 298 reflected in the total case counts, however, since these values are summations from the time of 299 vaccine initiation through the end of the 5 year period after the onset of the pandemic. Further, 300 in Figure 5 we illustrate the temporal effect of the coupled framework on the infection dynamics 301 in the LAR and HAR relative to the first model with no immigration or explicit effect of PTIs 302 on the transmission rate. When moderate asymmetry in \bar{R}_0 is assumed ($\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$ = 303 1.2), simulations using the decoupled framework suggest that a strategy where the HAR retains 304 all vaccines would be highly beneficial for that country (top panel of Figure 5; no PTIs are 305 projected to occur, and low case numbers are observed throughout). However, this occurs at the 306 expense of PTIs and infection burden in the LAR, which are both substantially higher. With 307 the more realistic coupled framework, immigration and increases in transmission illustrate that 308 this strategy is far less beneficial to the HAR than the decoupled framework would suggest, as 309 substantially higher case numbers and PTIs are predicted in this region. Although total cases in 310 the HAR increase slightly when vaccines are equally distributed under the coupled framework 311 (lower panel of Figure 5), substantial reductions in case numbers in the LAR result in fewer 312 PTIs in that country, and total combined case numbers are also slightly lower. To untangle the 313 effects of immigration and PTIs on dynamics in the coupled framework, we reproduce Figures 314 4 and 5 allowing for immigration only in Figures S7 and S8, respectively. In other words, these 315 figures represent a more optimistic evolutionary scenario in which the occurrence of a PTI 316 does not increase transmission rates in either the HAR or LAR. Overall, we show that vaccines 317 play an important role in minimizing cases (particularly severe cases) as well as potential viral 318 adaptation in both regions. We also emphasize that imperfect vaccinal and natural immunity 319 and asymmetries in population size and transmission rates add many nuances to this picture. 320

321 Caveats

A full list of caveats and future directions is presented in Supplementary Materials; we briefly 322 summarize them below. First, building on prior work and in order to focus on qualitative 323 features, we ignore heterogeneities within countries, such as due to age (30) or superspread-324 ing (31). Similarly, we have assumed simple scenarios for nonpharmaceutical interventions 325 as in (6). More granular, well-parameterized epidemiological models with these complexities 326 would lead to more accurate quantitative predictions. Furthermore, additional booster doses 327 may be administered that could alter population-level immune landscapes, and including these 328 in future models will be important for qualitative and quantitative predictions. Additionally, 329 we omit vaccine hesitancy (32), though simple extensions of our previous models with hesi-330 tancy (5, 6) could examine the resulting interplay with vaccine nationalism. Furthermore, we 331 have assumed the simplest evolutionary models, both for determining potential viral adaptation 332 rates as well as for simulating potential increases in transmission rates. As more data become 333 available, these should be refined (33-36), with possible directions including extending the 334 model to explicitly track the transmission of different strains, and accounting for potential re-335 ductions in the strength of vaccinal immunity (i.e. the parameters ϵ_{V_1} , ϵ_{V_2} , ϵ_1 , and ϵ_2) due to the 336 emergence of novel variants (37). Lastly, we assume that the seasonal transmission rates are 337 similar in both countries, though in reality they could differ. The online interactive application 338 (https://grenfelllab.shinyapps.io/vaccine-nationalism/) allows for an 339 in-depth exploration of the effect of different climate-driven seasonal transmission rates as well 340 as a broad range of assumptions related to NPIs and immuno-epidemiological parameters. 341

342

343 Conclusion

Even as vaccine production increases, a number of countries are choosing to share little or no vaccines with countries that have very low vaccine availability. Vaccine nationalism, dosing regimes, and host immune responses have important interactive effects, and these will substantially shape epidemiological dynamics and evolutionary potential in the medium term. Additionally, unstable vaccine supply will also increase variability in the timing or availability of first and second doses.

350

Using extensions of our prior work (5, 6), we incorporated vaccine sharing scenarios in two 351 countries whose infection dynamics are either otherwise independent or coupled through immi-352 gration of infectious individuals and evolution-driven increases in transmission rates. When 353 country profiles are symmetric, we find that sharing vaccines with countries that have low 354 availability decreases overall infections and may also mitigate potential antigenic evolution. 355 Asymmetries in population size or transmission rates introduce additional complexities, which 356 are particularly marked when natural and vaccinal immunity is weak. Nevertheless, our mod-357 els indicate that the redistribution of vaccine surpluses is likely advantageous in terms of epi-358 demiological and evolutionary outcomes in both countries and, by extension, globally. Ethical 359 arguments also support this policy (11, 12). Persistent elevated disease transmission in coun-360 tries with low vaccine availability also substantially undermines attempts at infection control 36 via stockpiling in the country with high vaccine availability, which is not accounted for when 362 disease transmission in both countries is assumed to be decoupled. Overall, our work high-363 lights the importance of continued efforts in quantifying the robustness of immunity following 364 vaccination. Furthermore, reevaluation of stockpiling policies as vaccine supplies increase is 365 imperative, and ramping up global vaccination efforts is crucial. 366

367

Supplementary Materials

369 See attached documents.

370 Acknowledgements

This work was funded in part by Open Philanthropy, the Natural Sciences and Engineering 371 Research Council of Canada through a Postgraduate-Doctoral Scholarship (CMSR), the Co-372 operative Institute for Modelling the Earth System (CIMES) (REB), the James S. McDonnell 373 Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and 374 Multi-scale Systems (CMSR, SAL), the C3.ai Digital Transformation Institute and Microsoft 375 Corporation (SAL), Gift from Google, LLC (SAL), the National Science Foundation (CNS-376 2027908, CCF1917819) (SAL), the U.S. CDC (BTG), Flu Lab (BTG). Author contributions: 377 CEW, CMSR, BTG designed the study. CEW and CMSR performed the simulations and anal-378 yses, and wrote the manuscript. SEM developed the Shiny application. All authors contributed 379 to interpreting the results and editing the manuscript. **Competing interests:** The authors have 380 no competing interests. 38

382 References

- 1. E. Dong, H. Du, L. Gardner, *The Lancet Infectious Diseases* **20**, 533 (2020).
- 2. F. P. Polack, et al., New England Journal of Medicine **383**, 2603 (2020). PMID: 33301246.
- 385 3. M. Voysey, et al., The Lancet **397**, 99 (2021).
- 4. L. R. Baden, et al., New England Journal of Medicine (2020).
- ³⁸⁷ 5. C. M. Saad-Roy, et al., Science **370**, 811 (2020).
- ³⁸⁸ 6. C. M. Saad-Roy, *et al.*, *Science* (2021).

- 7. C. M. Saad-Roy, S. A. Levin, C. J. E. Metcalf, B. T. Grenfell, *Journal of The Royal Society Interface* 18, 20200683 (2021).
- ³⁹¹ 8. D. P. Fidler, *Science* **369**, 749 (2020).
- ³⁹² 9. L. Eaton, *BMJ* **372** (2021).
- 393 10. J. Holder, Tracking coronavirus vaccinations around the world, 394 https://www.nytimes.com/interactive/2021/world/
- 395 covid-vaccinations-tracker.html.
- ³⁹⁶ 11. E. J. Emanuel, et al., Science **369**, 1309 (2020).
- ³⁹⁷ 12. E. J. Emanuel, F. Luna, G. O. Schaefer, K.-C. Tan, J. Wolff, *American Journal of Public* ³⁹⁸ *Health* 111, 371 (2021). PMID: 33566663.
- ³⁹⁹ 13. L. M. Herzog, O. F. Norheim, E. J. Emanuel, M. S. McCoy, *BMJ* **372** (2021).
- ⁴⁰⁰ 14. M. J. Keeling, A. Shattock, *Epidemics* **4**, 78 (2012).
- ⁴⁰¹ 15. H. Mamani, S. E. Chick, D. Simchi-Levi, *Management Science* **59**, 1650 (2013).
- ⁴⁰² 16. M. Salathé, J. H. Jones, *PLoS Computational Biology* **6**, e1000736 (2010).
- ⁴⁰³ 17. P. Klepac, R. Laxminarayan, B. T. Grenfell, *Proceedings of the National Academy of Sci-*⁴⁰⁴ ences 108, 14366 (2011).
- ⁴⁰⁵ 18. P. Klepac, I. Megiddo, B. T. Grenfell, R. Laxminarayan, *Journal of The Royal Society* ⁴⁰⁶ *Interface* 13, 20150907 (2016).
- 407 19. K. M. Bubar, et al., Science **371**, 916 (2021).
- ⁴⁰⁸ 20. N. Mulberry, P. Tupper, E. Kirwin, C. McCabe, C. Colijn, *medRxiv* p. 2021.02.23.21252309
 (2021).

- 410 21. J. Zahradník, *et al.*, *bioRxiv* (2021).
- 411 22. A. Rambaut, et al., Virological.org (2020). Https://virological.org/t/preliminary-genomic-
- characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-
- 413 spike-mutations/563.
- 414 23. H. M. Korevaar, et al., medRxiv (2020).
- 415 24. B. L. Rice, et al., Nature Medicine 27, 447 (2021).
- 416 25. J. M. Dan, et al., Science (2021).
- 417 26. S. P. Anand, et al., Cell Reports Medicine (2021).
- 418 27. V. Shinde, et al., New England Journal of Medicine **0**, null (0).
- 419 28. C. A. Prete, et al., medRxiv (2021).
- ⁴²⁰ 29. C. J. Reynolds, *et al.*, *Science* p. eabh1282 (2021).
- 421 30. J. S. Lavine, O. N. Bjornstad, R. Antia, Science (2021).
- 422 31. R. Laxminarayan, et al., Science 370, 691 (2020).
- 423 32. C. E. Wagner, et al., Frontiers in Public Health 8, 975 (2020).
- 33. C. M. Saad-Roy, A. B. McDermott, B. T. Grenfell, *The Journal of Infectious Diseases* 219,
 S46 (2019).
- 426 34. K. Koelle, S. Cobey, B. Grenfell, M. Pascual, Science 314, 1898 (2006).
- 427 35. E. M. Volz, S. L. Kosakovsky Pond, M. J. Ward, A. J. Leigh Brown, S. D. W. Frost, *Genetics*428 183, 1421 (2009).
- 429 36. E. M. Volz, K. Koelle, T. Bedford, *PLOS Computational Biology* 9, 1 (2013).

430 37. T. Kustin, *et al.*, *medRxiv* (2021).